(TMDX) TransMedics - Ratings and Ratios
Portable Organ Perfusion System, Lung, Heart, Liver Modules
TMDX EPS (Earnings per Share)
TMDX Revenue
Description: TMDX TransMedics August 03, 2025
TransMedics Group Inc. (NASDAQ:TMDX) is a commercial-stage medical technology company that is revolutionizing the field of organ transplantation. The companys flagship product, Organ Care System (OCS), is a portable organ perfusion, optimization, and monitoring system that replicates near-physiologic conditions for donor organs outside the human body, increasing the chances of successful transplantation.
The OCS platform includes various products such as OCS LUNG, OCS Heart, and OCS Liver, which cater to different organ transplant needs. Additionally, the company offers a national OCS program, a turnkey solution for outsourced organ retrieval, and provides OCS organ management and logistics services, including transportation and coordination activities. With a strong presence in the US and international markets, TransMedics is poised for growth.
From a performance perspective, key KPIs to watch include revenue growth, gross margin expansion, and the number of OCS systems sold or leased. The companys ability to increase its market share in the organ transplantation market, expand its product offerings, and enhance its logistics and management services will be crucial in driving future growth. With a market capitalization of $3.56 billion and a return on equity (ROE) of 21.88%, TransMedics has demonstrated its ability to generate returns for shareholders.
To further evaluate the companys prospects, it is essential to monitor its research and development (R&D) pipeline, regulatory approvals, and competitive landscape. Key metrics such as the number of patents filed or granted, clinical trial results, and the competitive positioning of its OCS platform will provide insights into TransMedics ability to maintain its market lead and drive innovation.
TMDX Stock Overview
| Market Cap in USD | 4,641m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2019-05-02 |
TMDX Stock Ratings
| Growth Rating | 80.3% |
| Fundamental | 72.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 32.2% |
| Analyst Rating | 4.22 of 5 |
TMDX Dividends
Currently no dividends paidTMDX Growth Ratios
| Growth Correlation 3m | 4.2% |
| Growth Correlation 12m | 73.4% |
| Growth Correlation 5y | 85.9% |
| CAGR 5y | 33.32% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.49 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.34 |
| Sharpe Ratio 12m | 0.62 |
| Alpha | 14.52 |
| Beta | 2.068 |
| Volatility | 61.13% |
| Current Volume | 1350.7k |
| Average Volume 20d | 897.6k |
| Stop Loss | 124.5 (-5.4%) |
| Signal | -0.46 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (91.8m TTM) > 0 and > 6% of Revenue (6% = 34.0m TTM) |
| FCFTA 0.13 (>2.0%) and ΔFCFTA 28.09pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 94.16% (prev 107.8%; Δ -13.65pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.19 (>3.0%) and CFO 178.0m > Net Income 91.8m (YES >=105%, WARN >=100%) |
| Net Debt (-1.43m) to EBITDA (122.2m) ratio: -0.01 <= 3.0 (WARN <= 3.5) |
| Current Ratio 7.69 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (40.7m) change vs 12m ago 14.19% (target <= -2.0% for YES) |
| Gross Margin 60.28% (prev 59.29%; Δ 0.99pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 65.41% (prev 51.06%; Δ 14.36pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 5.74 (EBITDA TTM 122.2m / Interest Expense TTM 14.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.63
| (A) 0.56 = (Total Current Assets 613.0m - Total Current Liabilities 79.7m) / Total Assets 946.0m |
| (B) -0.41 = Retained Earnings (Balance) -383.3m / Total Assets 946.0m |
| (C) 0.09 = EBIT TTM 80.4m / Avg Total Assets 865.8m |
| (D) 0.60 = Book Value of Equity 355.2m / Total Liabilities 590.8m |
| Total Rating: 3.63 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 72.54
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield 2.60% = 1.30 |
| 3. FCF Margin 21.30% = 5.33 |
| 4. Debt/Equity 1.31 = 1.70 |
| 5. Debt/Ebitda -0.01 = 2.50 |
| 6. ROIC - WACC (= -2.75)% = -3.44 |
| 7. RoE 31.42% = 2.50 |
| 8. Rev. Trend 95.84% = 7.19 |
| 9. EPS Trend 79.32% = 3.97 |
What is the price of TMDX shares?
Over the past week, the price has changed by +0.78%, over one month by +17.24%, over three months by +10.57% and over the past year by +60.47%.
Is TransMedics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TMDX is around 150.04 USD . This means that TMDX is currently undervalued and has a potential upside of +14.06% (Margin of Safety).
Is TMDX a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TMDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 141.9 | 7.9% |
| Analysts Target Price | 141.9 | 7.9% |
| ValueRay Target Price | 173.2 | 31.7% |
TMDX Fundamental Data Overview November 01, 2025
P/E Trailing = 53.4606
P/E Forward = 52.356
P/S = 8.7344
P/B = 12.439
Beta = 2.068
Revenue TTM = 566.4m USD
EBIT TTM = 80.4m USD
EBITDA TTM = 122.2m USD
Long Term Debt = 509.3m USD (from longTermDebt, last fiscal year)
Short Term Debt = 8.24m USD (from shortTermDebt, last quarter)
Debt = 464.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.43m USD (from netDebt column, last quarter)
Enterprise Value = 4.64b USD (4.64b + Debt 464.7m - CCE 466.2m)
Interest Coverage Ratio = 5.74 (Ebit TTM 80.4m / Interest Expense TTM 14.0m)
FCF Yield = 2.60% (FCF TTM 120.6m / Enterprise Value 4.64b)
FCF Margin = 21.30% (FCF TTM 120.6m / Revenue TTM 566.4m)
Net Margin = 16.20% (Net Income TTM 91.8m / Revenue TTM 566.4m)
Gross Margin = 60.28% ((Revenue TTM 566.4m - Cost of Revenue TTM 224.9m) / Revenue TTM)
Gross Margin QoQ = 58.80% (prev 61.38%)
Tobins Q-Ratio = 4.90 (Enterprise Value 4.64b / Total Assets 946.0m)
Interest Expense / Debt = 0.75% (Interest Expense 3.49m / Debt 464.7m)
Taxrate = 5.59% (1.29m / 23.0m)
NOPAT = 75.9m (EBIT 80.4m * (1 - 5.59%))
Current Ratio = 7.69 (Total Current Assets 613.0m / Total Current Liabilities 79.7m)
Debt / Equity = 1.31 (Debt 464.7m / totalStockholderEquity, last quarter 355.2m)
Debt / EBITDA = -0.01 (Net Debt -1.43m / EBITDA 122.2m)
Debt / FCF = -0.01 (Net Debt -1.43m / FCF TTM 120.6m)
Total Stockholder Equity = 292.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 9.70% (Net Income 91.8m / Total Assets 946.0m)
RoE = 31.42% (Net Income TTM 91.8m / Total Stockholder Equity 292.1m)
RoCE = 10.03% (EBIT 80.4m / Capital Employed (Equity 292.1m + L.T.Debt 509.3m))
RoIC = 9.71% (NOPAT 75.9m / Invested Capital 781.1m)
WACC = 12.46% (E(4.64b)/V(5.11b) * Re(13.64%) + D(464.7m)/V(5.11b) * Rd(0.75%) * (1-Tc(0.06)))
Discount Rate = 13.64% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 9.19%
[DCF Debug] Terminal Value 58.71% ; FCFE base≈120.6m ; Y1≈111.3m ; Y5≈100.4m
Fair Price DCF = 25.57 (DCF Value 873.9m / Shares Outstanding 34.2m; 5y FCF grow -9.78% → 3.0% )
EPS Correlation: 79.32 | EPS CAGR: 38.62% | SUE: 0.81 | # QB: 0
Revenue Correlation: 95.84 | Revenue CAGR: 73.96% | SUE: -0.14 | # QB: 0
Additional Sources for TMDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle